日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study

阿贝西诺他（一种组蛋白去乙酰化酶抑制剂）治疗复发或难治性滤泡性淋巴瘤患者：一项多中心、单臂 II 期研究

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-026-02646-z
Gui, Lin; Liu, Haifeng; Wang, Huaqing; Cao, Junning; Li, Yufu; Yu, Yong; Gao, Yuhuan; Li, Zhenling; Shen, Jianzhen; Zhang, Lei; Zhang, Qingyuan; Pan, Hongming; Zheng, Meifang; Ke, Xiaoyan; He, Hesheng; Guo, Shuangshuang; Wang, Yihao; Xu, Xiaohong; Zou, Liqun; Wu, Wentao; Shi, Yuankai
淋巴瘤
表观遗传
乙酰化
发表日期：2026
文献求助 收藏

Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR Study

瑞维替尼治疗伴有中枢神经系统转移的EGFR突变型非小细胞肺癌患者：来自III期REZOR研究的中枢神经系统疗效

期刊:Cancer Communications
影响因子:24.9
doi:10.34133/cancomm.0018
Yang, Sheng; Zhao, Yanqiu; Sun, Meili; Bi, Minghong; Zhu, Bo; Chen, Zhaohong; Yu, Huiqing; Zhang, Liangming; Wu, Lin; Zhou, Rui; Yao, Wenxiu; Li, Xingya; Han, Zhigang; Wang, Ke; Wang, Lijun; Wen, Meiling; Guo, Yanzhen; Lin, Yingcheng; Sun, Shenghua; Guo, Shuliang; Yi, Tienan; Zhao, Wenhua; Yu, Zhuang; Qin, Jianwen; Pan, Yueyin; He, Zhiyong; Ye, Feng; Shi, Huaqiu; Fang, Jian; Ma, Rui; Lu, Hong; Zhang, Hua; Shi, Jianhua; Gao, Jinghua; Cui, Jiuwei; Li, Manxiang; Yi, Shanyong; Cang, Shundong; Shu, Yongqian; Zhang, Don; Peng, Jirong; Gao, Feng; Wang, Tingting; Zhou, Anqi; Shi, Yuankai
肺癌
肿瘤
肿瘤免疫
EGF
神经科学
EGFR
细胞生物学
发表日期：2026
文献求助 收藏

DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer

DSG2+癌干细胞与FAP+肌成纤维细胞共定位于肿瘤边界，决定了非小细胞肺癌免疫疗法的疗效

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202514543
Fan, Guangyu; Tang, Le; Xie, Tongji; Yang, Mengwei; Li, Lin; Yang, Sheng; Xing, Puyuan; Han, Xiaohong; Shi, Yuankai
肺癌
成纤维细胞
肿瘤
发育与干细胞
肿瘤免疫
FAP
干细胞
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Spatial transcriptomics reveals molecular heterogeneity and subtype-specific therapeutic targets in small cell lung cancer

空间转录组学揭示小细胞肺癌的分子异质性和亚型特异性治疗靶点

期刊:npj Precision Oncology
影响因子:8
doi:10.1038/s41698-025-01243-7
Xie, Tongji; Tang, Le; Fan, Guangyu; Han, Xiaohong; Shi, Yuankai
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026)

过去30年（1997-2026年）表皮生长因子受体酪氨酸激酶抑制剂用于治疗非小细胞肺癌

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000004016
Xie, Zucheng; Chen, Xinrui; Gao, Ruyun; Yang, Mengwei; Han, Xiaohong; Sun, Yan; Shi, Yuankai
肺癌
肿瘤
肿瘤免疫
信号转导
细胞生物学
发表日期：2026
文献求助 收藏

First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

在中国RAS/BRAF野生型转移性结直肠癌患者中，一线治疗方案为抗EGFR单克隆抗体西妥昔单抗β联合FOLFIRI方案与单用FOLFIRI方案的比较：一项随机、3期临床试验

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02229-4
Shi, Yuankai; Ba, Yi; Wang, Junye; Xiong, Jianping; Gu, Kangsheng; Chen, Yigui; Zheng, Zhendong; Wang, Zishu; Guo, Weijian; Cheng, Ying; Yin, Xianli; Liu, Yunpeng; Bai, Yuxian; Li, Enxiao; Li, Qi; Zhu, Liangjun; Li, Wei; Jiang, Da; He, Jingdong; Chen, Jiansi; Sun, Jianguo; Hou, Sheng
单克隆抗体
肿瘤
肠癌
肿瘤免疫
EGF
BRAF
EGFR
RAS
发表日期：2025
文献求助 收藏

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib

一项前瞻性、多中心、全面的基因组特征研究，针对一线奥希替尼治疗失败的EGFR突变晚期非小细胞肺癌患者。

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02481-8
Shi, Yuankai; Lv, Dongqing; Feng, Weineng; Liu, Shuoyan; Xing, Puyuan; Yu, Yan; Yin, Jun; Ren, Xiubao; Zhang, Junqiang; Han, Gaohua; Zhang, Yongchang; Cang, Shundong; Chen, Jun; Chen, Enguo; Meng, Lingxin; Zhang, Yong
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2025
文献求助 收藏

Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025)

过去26年（2000-2025年）免疫检查点抑制剂在实体瘤和淋巴瘤治疗中的应用

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01734-x
Huang, Liling; Zhu, Haohua; Shi, Yuankai
淋巴瘤
免疫/内分泌
发表日期：2025
文献求助 收藏

The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma

MARCO+肿瘤相关巨噬细胞与CTSE+肿瘤细胞的共定位决定了肝内胆管癌的不良预后

期刊:Hepatology
影响因子:15.8
doi:10.1097/HEP.0000000000001138
Fan, Guangyu; Tao, Changcheng; Li, Lin; Xie, Tongji; Tang, Le; Han, Xiaohong; Shi, Yuankai
巨噬细胞
肿瘤
肿瘤免疫
MARCO
巨噬细胞
ARC
胆管癌
细胞生物学
肿瘤细胞
免疫/内分泌
发表日期：2025
文献求助 收藏

Advancing patient-centered care: progress and prospects of patient-reported outcomes in oncology clinical trials in China

推进以患者为中心的医疗：中国肿瘤临床试验中患者报告结局的进展与展望

期刊:The Lancet Regional Health Western Pacific
影响因子:8.1
doi:10.1016/j.lanwpc.2025.101630
Xie, Zucheng; Tang, Le; Shi, Yuankai
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏